Position in URGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$476,649
-$179,228 QoQ
Shares Held
26,510
-5.3% QoQ
Ownership
0.054%
of shares outstanding
% of Portfolio
0.13%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in URGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026HighVista Strategies LLC holds $224,607,258 across 76 Biotechnology names. URGN ranks #72 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
113,254 | $12,610,832 | |
| 2 | PRAX |
Praxis Precision Medicines, Inc.
|
26,323 | $8,481,007 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
197,051 | $7,584,492 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
146,264 | $7,377,556 | |
| 5 | PCVX |
Vaxcyte, Inc.
|
124,647 | $7,243,237 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
69,309 | $6,740,300 | |
| 7 | TERN |
Terns Pharmaceuticals, Inc.
|
114,307 | $6,026,265 | |
| 8 | GPCR |
Structure Therapeutics Inc.
|
123,909 | $5,972,413 |
All Filings in URGN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $476,649 | 26,510 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $655,877 | 28,005 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $636,125 | 31,886 | Shares | Sole | 2025-11-14 | |
| 2024-09-30 | $489,788 | 38,566 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||